Structure of the unit
The BaRITOn unit is made of three Inserm labeled teams who share their common interest in human cancer translational research.
History, localization of the unit
The BordeAux Research In Translational Oncology (BaRITOn) U1053 unit is made of three Inserm labeled teams who decided in 2015 to share their common interest in human cancer translational research. Indeed, the unit originated in 2016 from the merger of 3 pre-existing labs: INSERM U1053 “Pathophysiology of Liver Cancer”, INSERM U853 “Helicobacter infection, Inflammation and Cancer” and EA 2406 “Histology and Molecular Pathology of Tumors”.
The Inserm unit BaRITOn (Bordeaux Research In Translational Oncology) - U1053 was successively directed by Jean Rosenbaum (until July 2016) and Jean-Philippe Merlio (until March 2020) and is currently directed Violaine Moreau (from April 2020).
The unit is strategically situated on the Health Campus of the University of Bordeaux in close proximity to one of the 3 University Hospitals.
Structure of the unit
The BaRITOn unit is composed of 67 persons (without interns), including 47 with permanent position and 20 under short-term contract. The Unit includes 4 full-time researchers (2 DR2 Inserm and 2 CRCN CNRS), 6 lecturers from Bordeaux University, 17 PU-PH/MCU-PH from the Bordeaux CHU, 4 Professors emeritus, 10 technical staffs, 4 post-docs and 13 PhD students.
The Unit is composed of the three following teams: Team1 “Liver Cancer and Tumor Invasion” is headed by Violaine Moreau (DR2 Inserm) and Frédéric Saltel (DR2 Inserm), Team2 “Helicobacter infection: Inflammation and Cancer” is directed by Philippe Lehours (PU-PH) and Team3 “Oncogenesis of cutaneous lymphomas” is directed by Jean-Philippe Merlio (PU-PH).
Each team has strong connections with the University Hospital of Bordeaux and is using relevant experimental models in mice or using cell lines of the three cancer types: liver carcinoma, gastric cancer linked to Helicobacter infection and cutaneous lymphomas. Clinicians, pathologists, bacteriologists and geneticists of the University Hospital of Bordeaux are members of each team that permits access to human samples, the setup of correlative translational studies, clinical trials and the development of patients’ derived models for each tumor types or by using pathogenic strains for Helicobacter infection.
Violaine MOREAU firstname.lastname@example.org